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The aim of this study was to assess the feasibility of a randomized controlled trial 
(PFM) treatment in women with bladder pain syndrome (BPS). Prolonged PFM 
tension contributes to the bladder pain, urinary frequency and urgency associated 
with BPS. Pelvic health physiotherapists routinely provide intravaginal myofascial 
release (MFR) to the PFMs in order to effectively reduce symptoms. Rapid access 
A TW was designed so as to allow men with chronic pelvic pain to self- treat, 
and this may be effective in women with BPS. For 6 weeks, two groups received 
weekly physiotherapist- provided MFR, and were monitored for a further 6- week 
follow- up period. One group also used a TW at home three times a week through-
out the pilot. Weekly outcome measures of BPS symptoms and quality of life 
were recorded. A clinically meaningful difference in Interstitial Cystitis Symptoms 
Index and Interstitial Cystitis Problem Index score changes between groups was 
group = 6.20 ± 0.83 and 5.00 ± 1.41, respectively), and a difference was observed 
during the follow- up period (control group = 4.50 ± 1.73 and 4.00 ± 2.44, respec-
events. Using the TW appears to have enhanced physiotherapy treatment during 
the initial 6 weeks, and improved symptoms during the 6- week follow- up period. 
The TW may be a clinically useful tool for long- term management of BPS. The 
feasibility of the study method was proven, some alterations were recommended 
and an RCT is now warranted.
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Bladder pain syndrome (BPS) is an umbrella 
-
trum of chronic bladder conditions that form a 
subgroup of chronic pelvic pain (CPP) (Engeler 
et al. 2012). Sufferers experience pelvic pain 
without infection that worsens when the uri-
also a persistent urge to void or an increase in 
frequency (Fall et al. et al. 2010). 
The prevalence of BPS is estimated to be 2.7–
7.9% in women and 0.4–1.9% in men (Berry 
et al.
When the condition was initially described, it 
was thought to be associated with a persistent in-
fection of the bladder lining because of the simi-
larity in symptoms, and therefore, it was named 
-
der investigations of patients with BPS often 
(Hanno et al. 2010).
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The aetiology of BPS is unclear, and is cur-
rently thought to involve an initial insult to the 
-
logical and endocrine responses that may devel-
op into a systemic pain syndrome (Nickel et al. 
2010). Other systemic, non- bladder conditions 
-
algia are known risk factors for the development 
of BPS, which suggests that there is a potential 
centrally driven predisposition to widespread 
hyperalgesia (Warren et al. et al. 
2012). Changes occur in the activity of affer-
ent nerves of the bladder lining, causing urinary 
urgency and frequency (Daly et al. 2011), and 
emotional responses to symptoms may promote 
González et al. 2014). Ultrasound assessment has 
also become less mobile and painful on palpation 
(Fall et al. et al. 2012). Pastore 
& Katzman (2012) suggested that reduced mobil-
ity would prevent the PFMs from performing the 
-
urgency and frequency. Quintner et al. (2014) 
proposed that both the altered mechanosensation 
and increased resting tension of the muscles are 
then be maintained centrally in BPS (Bove et al. 
2003). Frawley (2015) suggested that this should 
et al. 
(2007) found that bladder pain and urgency per-
sist after bladder treatment for BPS if PFM pal-
pation remains painful. This supports the notion 
that PFM pain, tension and bladder symptoms 
are linked.
Sufferers of BPS experience painful and regu-
weeks or months (Sutcliffe et al. 2015b), and 
therefore, they remain constantly vigilant for po-
tential triggers. This disrupts employment and 
social activities, reducing their quality of life 
(Rapariz- González et al. et al. 
2015a). The population with BPS have a higher 
incidence of depression, anxiety and insomnia 
than matched controls [risk compared to nor-
(2.2–2.6), 2.4 (2.2–2.7) and 2.1 (1.8–2.4), re-
et al.
to exhibit poor illness coping strategies (Naliboff 
et al. 2015).
Limiting treatment to the bladder is ineffective, 
and therefore, international guidelines promote a 
multidisciplinary approach to symptom and disa-
bility management (Engeler et al.
2015). Physiotherapy treatment aims to restore 
normal PFM tension and range of movement, de-
sensitize muscle nociceptors, and promote opti-
mal bladder and bowel function (Bø et al.
Frawley 2015). Intravaginal PFM myofascial re-
lease (MFR) is a treatment that is routinely pro-
vided by pelvic health physiotherapists.
MFR of the PFMs in participants with BPS 
that were of appropriate methodological qual-
ity. Two further case series investigating MFR 
for chronic prostatitis (n = 2) (Van Alstyne et al. 
2010) and women with CPP (n = 6) (Montenegro 
et al. 2010) were excluded from the analysis. 
bladder pain, and urinary urgency and frequency 
(all P et al.
Anderson et al. et al. 2009, 
2012). Chiarioni et al. (2010) found that MFR 
-
cal stimulation, but reported that it produced a 
P -
sity. These studies combined several conservative 
therapies, including relaxation and psychological 
coping strategies, and varied in the application of 
While this makes it impossible to determine the 
optimal PFM manual therapy, a trend was ob-
served for improved outcomes with MFR applied 
over a duration of at least 5 weeks and lasting 
more than 10 min per session, and using an in-
dividualized approach to the patient presentation 
that included some contract–relax stretching and 
sustained, gentle compression.
It is thought that MFR produces a cerebral 
and corticospinal analgesic response (Piché et al. 
2009), modulates PFM nociceptors and mechan-
et al. 2014), 
and improves resting PFM tension (Frawley 
-
Accessing urgent physiotherapy treatment can 
obtain (Sutcliffe et al. 2015a), and symptom res-
olution can require a substantial, labour- intensive 
physiotherapy time commitment (Anderson et al. 
2011a).
Anderson et al. (2011a) developed a therapeu-
tic wand (TW) to allow patients with urological 
CPP to access their own PFMs and perform inde-
pendent MFR. Several trials by the same clinical 
group on mostly male participants with CPP at-
tending a US pelvic pain clinic have demonstrat-
et al.
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-
served in the pelvic pain of 94% of patients 
(P
the TW itself could not be determined because 
there was no control group for comparison, and 
the intervention included psychological strategies 
for improving coping, such as mindfulness. The 
observed improvements may suggest that the TW 
reproduces the suggested analgesic and neuro-
muscular modulating effects of physiotherapist- 
applied MFR (Piché et al.
Using a TW for MFR of PFM hypertonicity 
is routinely taught in specialist physiotherapy 
courses (e.g. Ruth Jones’s “The Pelvic Detective 
Course: Physiotherapy Assessment and Treatment 
Wales, Cardiff, May 2014), and discussed in text-
books (Chaitow & Lovegrove Jones 2012) and 
-
proved by providing them with self- management 
tools (Dufour et al. 2015), and this is known to 
improve their perception of pain and disability 
(Denison et al. 2004). Therefore, self- treatment 
is itself a powerful method of improving health 
outcomes (Bodenheimer et al. 2002), and along-
side physiotherapy, the TW has the potential to 
enhance these for patients with BPS by increas-
ing treatment frequency and allowing independ-
to manage BPS, further investigation is warrant-
investigated the utility or potential effect of a 
TW in women with BPS. The present pilot study 
aimed to test the feasibility of a randomized con-
trolled trial (RCT) investigating the use of a TW 
in a sample of women with BPS.
A volunteer sample of women diagnosed with 
BPS was drawn from urology and urogynae-
cology consultants at a Welsh private hospital. 
Each consultant reviewed the patients who had 
criteria (see Box 1), and appropriate potential 
participants (n = 37) were sent a letter of invi-
tation. Patients who responded to the invitation 
(n = 23, 62%) were invited to discuss participa-
further detailed comparison with the inclusion/
exclusion criteria. Ten women consented to par-
excluded at the initial assessment because she 
had atrophic vaginitis. Participants underwent 
computer- generated block randomization into a 
control group and a TW group. Demographic 
characteristics were gathered for comparison 
with previous data. Randomization was not 
Box 1. Participant inclusion and exclusion crite-
pain syndrome
Inclusion criteria:
females
age 18–65 years (upper limit to reduce the 
risk of vaginal bleeding upon treatment with 
the TW) (Castelo- Branco et al. 2005)
a diagnosis of BPS or interstitial cystitis as 
for the Study of BPS (van de Merwe et al. 
2008)
symptoms of bladder pain, urgency and fre-
quency in at least the last month prior to 
study participation
as per the European Urology Association 
Bladder Pain Syndrome guidelines (Fall 
et al. 2010)
ability to attend the department for treatment
ability to give informed consent
the participant to manipulate the TW for 
self- treatment
Exclusion criteria:
concurrent diagnoses that may cause pelvic 
disease, endometriosis, dysmenorrhoea and 
irritable bowel syndrome (Alagiri et al. 1997)
postmenopausal atrophic vaginitis because of 
the risk of vaginal trauma and bleeding with 
TW use (Castelo- Branco et al. 2005)
reasonable suspicion of other treatable pa-
thologies, such as urinary tract infection (van 
de Merwe et al. 2008)
a lack of appropriate completed diagnos-
tic investigations, such as urinalysis, or 
urodynamic or cystoscopic assessment, as 
per National Institute of Health and Care 
Excellence guidance (NICE 2013) 
pregnancy or planning to conceive
symptoms associated only with menses 
(FitzGerald et al. 2009)
undergoing concurrent treatments that could 
affect outcome, such as bladder Botox or an-
algesic injections, sacral neuromodulation, or 
physiotherapy treatment
previous pelvic health physiotherapy treatment
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for the effect of age, parity, duration of blad-
der symptoms, number of surgeries or analgesia 
use on MFR treatment response. No acceptable 
sham treatment exists since any intravaginal 
penetration potentially provides a therapeutic re-
duction in muscle tone (Weiss 2001), and there-
fore, participants were not blinded.
Standard multimodal physiotherapy assess-
ment and treatment for BPS, including 15 min 
et al. 2012), 
was provided weekly to both groups for 6 weeks 
by a single, experienced specialist pelvic health 
physiotherapist within a private hospital clinic 
setting (for details, see Fig. 1 and Table 1).
-
ceived a TW information sheet (see Fig. 6 in 
TW safely for 15 min, three times a week, be-
tween each physiotherapy session and during the 
6- week follow- up period. Both groups were in-
structed to carry out daily PFM active release ex-
ercises in sitting or standing during the 12- week 
study period. The primary outcome measures re-
corded weekly were the O’Leary–Sant Interstitial 
Cystitis Symptom Index (ICSI) and Interstitial 
Cystitis Problem Index scores (ICPI), and sec-
ondary measures of genital- pain- related quality 
of life, PFM pain on palpation, overall pain, and 
urinary urgency and frequency were also gath-
ered. The TW group also completed a 3- month 
compliance diary. Participants returned after a 
further 6- week follow- up period for reassessment.
The Premium TheraWand® (Fig. 2) is made 
from medical- grade acrylic approved by the US 
Food and Drug Administration, is available in 
the UK, and the manufacturer (Pelvic Therapies, 
Inc., Carlsbad, CA, USA) provides quality and 
third being used internally for treatment.
Ethical approval for the present study 
was gained from the University of Bradford 
and the National Health Service Research 
Ethics Committee, and it was registered with 
ClinicalTrials.gov (NCT02743962).
In the proposed RCT, inferential statistics would 
be applied as appropriate to infer statistical 
2014). However, this has little power with small 
Figure 1. The Premium TheraWand®
and (right) treatment end.
Table 1.
(Bø et al.
Treatment Frequency
Education regarding female internal and external pelvic anatomy,  
the PFMs, and the pathology of BPS
Initial assessment/treatment session only
Education regarding correct PFM contraction for urinary urge 
provided in sitting (clothed), then participants were guided to 
produce a correct contraction (if able) during PFM assessment
Repeated during each treatment session as required
Correct defecation dynamics position, low force and diaphragmatic 
breathing to achieve defecation
Initial assessment/treatment session, sheet also provided 
6- week treatment period as required
Bladder retraining information, including urge suppression, trigger 
avoidance and voiding timing
As above
As above
Mindfulness relaxation As above
Myofascial release of the PFMs: after initial PFM assessment, 
gentle compression was applied at 5 o’clock and 7 o’clock on the 
horizontal axis, then contract–relax stretching throughout the PFMs 
focusing on areas of tension and pain, followed by sweeps from 
presentation, but loosely followed this structure
15 min weekly for 6 weeks 
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Figure 2.
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-
2012). Therefore, data analysis was conducted 
using descriptive statistics and compared with 
the known minimal clinically important differ-
ences (MCIDs) for each outcome measure (see 
Table 2) to inform examination of the trends ob-
served (Peat & Barton 2005). For data analysis 
purposes, the patient- reported outcome measures 
used were considered to be interval data be-
cause these have been demonstrated to employ a 
ratio scale, and therefore, interval scale proper-
ties (Price et al.
standard deviations are presented.
All nine participants completed the study, and 
no adverse events were reported. The partici-
pants’ mean age, parity, self- reported duration of 
symptoms, analgesia use and number of surger-
for them to be considered suitably homogene-
ous at baseline (see Table 1). Baseline symptom 
scores in the TW group (ISCI = 12.4 ± 2.07, 
ICPI = 11.20 ± 3.91) were higher than in the 
control group (ICSI = 10.50 ± 2.65, ICPI = 10.00 ± 
2.68), although not by enough to constitute a 
clinically meaningful difference.
control and TW groups are shown in Table 3.
Both groups demonstrated a trend for a reduc-
tion in ICSI and ICPI scores from baseline to week 
12, with most of the improvement being observed 
between baseline and week 2 (ISCI change: con-
ICPI change: control group = 3.50 ± 1.29, TW 
group = 3.60 ± 1.67) (Table 4 and Figs 3 & 4). 
During the initial 6- week physiotherapy treat-
ment period, both groups achieved improvements 
in all outcome measures to a level reaching the 
MCID. The change in score in the TW group was 
higher than in the control group, although the 
difference between the groups did not reach the 
MCID (ICSI change: control group = 4.25 ± 0.95, 
group = 3.50 ± 1.91, TW group = 5.00 ± 1.41).
Table 2.
Numerical Rating Scale 
Outcome measure MCID standard Reference
ICSI and ICPI –4 points = moderate improvement
–7 points = great improvement
–9 points = symptom resolution
Lubeck et al. (2001)
GUPI –4 points = MCID
–7 points = treatment responder
Clemens et al. (2009)
PUF Reduction of 0.5 of one standard deviation Norman et al. (2003)
VAS –10 mm Bourdel et al. (2015)
therapeutic wand use 
–5 points = very effective 
–2 points = moderately effective 
–1 point = not effective
Anderson et al. (2011a) 
 
Table 3.
Prescription
Age (years) Parity Symptom duration (years) Analgesic drugs Antimuscarinic drugs Number of surgeries
Control group    
49 2 10 Nil Solifenacin 2
54 0  4 Naproxen Nil 1
18 0  1 Gabapentin and paracetamol Nil 0
24 0  2 Amitriptyline Oxybutynin 0
Therapeutic wand group
26 1 11 Gabapentin Solifenacin 1
27 0  7 Paracetamol Oxybutynin 1
36 2  2 Pregabalin Nil 0
31 1  1 Nil Nil 0
43 2  5 Paracetamol and gabapentin Darifenacin 0
J. Bond et al.
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During the 6- week follow- up period, the 
mean ICSI and ICPI scores continued to reduce 
in the TW group (ICSI change = 1.80 ± 1.73, 
ICPI change = 2.00 ± 0.70), whereas the control 
group plateaued (ICSI change = 0.00 ± 0.95, ICPI 
change = 0.25 ± 1.29). The secondary measures 
From baseline to week 12, both groups had a 
reduction in ICSI and ICPI scores that met the 
MCID (four points) in all but the control group 
ICPI score change (3.75 ± 2.44). The TW group 
had twice the score change of the control group 
(see Table 4). Again, this trend was repeated in 
all the secondary measures, where the overall 
change in the TW group was greater than in the 
difference between the score changes reported 
by the TW and control groups after 12 weeks of 
intervention.
the basis of the change in their ICSI score after 
12 weeks, the control group was split between 
the bottom two levels (non- responder, n 
moderately improved, n = 3), whereas the TW 
(greatly improved, n 
n = 2). At 12 weeks, the utility of the TW was 
categorized by change in Numerical Rating Scale 
Table 4. Change in ICSI and ICPI scores over the duration of the study in the control and therapeutic wand (TW) groups: 
Problem Index
Change in score (mean ± SD)
Outcome measure 0–2 weeks 2–6 weeks 0–6 weeks 6–12 weeks 0–12 weeks
ICSI:      
 control group 3.75 ± 2.06 0.50 ± 1.29 4.25 ± 0.95 0.00 ± 0.95 4.25 ± 1.73
 TW group 4.00 ± 1.00 2.20 ± 1.09 6.20 ± 0.83 1.80 ± 1.73 8.00 ± 2.12
ICPI
 control group 3.50 ± 1.29 0.00 ± 0.80 3.50 ± 1.91 0.25 ± 1.29 3.75 ± 2.44
 TW group 3.60 ± 1.67 1.40 ± 0.89 5.00 ± 1.41 2.00 ± 0.70 7.00 ± 1.87
Figure 3. Line graph showing the participant mean O’Leary–Sant Interstitial Cystitis Symptom Index (ICSI) score 
change over the duration of the study in the control (––) and therapeutic wand (- - - - ) groups.
Figure 4. Line graph showing the participant mean O’Leary–Sant Interstitial Cystitis Problem Index (ICPI) score 
change over the duration of the study in the control (––) and therapeutic wand (- - - - ) groups.
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(NRS) pain on palpation scores, and all par-
ticipants were within the very effective bracket 
(n = 5). There was good compliance with use of 
the instrument in the TW group, with a median 
frequency of two times a week throughout the 
study.
The baseline characteristics of the sample were 
similar to those that have previously been report-
ed, and both the control and TW groups’ mean 
ICSI (10.5 and 12.4, respectively) and ICPI (10.0 
and 11.2, respectively) scores were similar and 
within one standard deviation of previous studies 
(ICSI = 13.0 ± 4.8, ICPI = 12.1 ± 3.3, FitzGerald 
et al.
FitzGerald et al. 2012). Therefore, the groups 
were considered representative of the wider 
population with BPS and suitably homogeneous 
at baseline.
For all outcome measures, the greatest im-
treatment, with both groups achieving a change 
in score that almost met the MCID (4) for the 
ICSI and ICPI score changes (control group: 
group: ICSI = 4.0 ± 1.0, ICPI = 3.60 ± 1.67). 
-
cating that the standard multimodal physiother-
apy intervention for BPS can quickly provide a 
clinically meaningful reduction in bladder pain, 
urinary urgency and frequency, quality of life, 
et al.
Anderson et al. et al. 2009, 
et al. 2010). However, despite 
the difference in the frequency of MFR treat-
control group received two, and the TW group 
received a mean of six when TW use was in-
cluded), the change in symptoms was similar 
between groups. This raises the possibility that 
using a TW provides no advantage over standard 
multimodal physiotherapy in the initial treatment 
period, or that the rate of symptom improvement 
has a ceiling. Since the only comparative data 
for TW use was recorded monthly, the impor-
et al. 
2011a, b, 2015). It is important that this is fur-
ther investigated to ascertain when the TW may 
to decide the frequency of outcome measures re-
corded, and to provide clinical guidance in any 
adjunctive TW use in this population.
peripheral nociceptors and mechanoreceptors 
that produce spontaneous pain, further neuroin-
et al. 
2014) by improving localized venous congestion 
and reducing muscular tension (Chaitow 2007). 
A reduction in pain was observed in both groups 
after 2 weeks, which suggests that desensitiza-
tion of the PFMs had occurred (NRS PFM pain 
Table 5. Mean baseline and mean change in secondary outcome measure scores over the course of the study in the control 
muscle
Change in outcome measure score (mean ± SD)†
Outcome measure Baseline score (mean ± SD) 0–6 weeks 6–12 weeks 0–12 weeks
GPI:
 control group 27.00 ± 7.07  9.25 ± 4.85  1.25 ± 0.95 10.50 ± 4.04
 TW group 31.00 ± 4.89 11.60 ± 5.50  3.40 ± 1.51 15.00 ± 6.25
PUF:
 control group 14.00 ± 3.56  3.75 ± 1.70  0.75 ± 0.96  4.50 ± 2.64
 TW group 16.20 ± 1.64  6.80 ± 1.79  2.20 ± 1.30  9.00 ± 2.83
VAS* (urgency):
 control group 60.00 ± 18.25 20.00 ± 8.16 10.00 ± 8.16 30.00 ± 8.16
 TW group 70.00 ± 21.21 42.00 ± 8.36  6.00 ± 5.48 48.00 ± 13.03
VAS* (bladder pain):
 control group 57.50 ± 15.00 22.50 ± 5.00  2.50 ± 0.50 25.00 ± 10.00
 TW group 68.00 ± 17.50 42.00 ± 16.43  4.00 ± 5.48 46.00 ± 16.73
VAS* (overall pain):
 control group 57.50 ± 15.00 25.00 ± 12.91  2.50 ± 9.57 27.50 ± 9.57
 TW group 66.00 ± 20.70 30.00 ± 12.25  8.00 ± 8.37 41.00 ± 16.43
NRS for PFM pain:
 control group  7.25 ± 1.50  4.75 ± 1.50  0.25 ± 0.50  5.00 ± 1.41
 TW group  8.00 ± 0.70  6.00 ± 1.22  1.20 ± 1.09  7.00 ± 0.45
*Scores in millimetres.
†Results in boldface type signify changes greater than the minimally clinically important difference in score.
J. Bond et al.
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change: control group = –1.5, TW group = –2.0). 
This supports previous studies demonstrating a 
et al. 
et al.
et al. 2010).
A competing counterirritation stimulus, such as 
that produced by palpating painful muscle tissue, 
has been shown to activate cortical processes, 
producing a descending modulation of spinal no-
ciception and an analgesic response (Piché et al. 
2009). This may explain the observed concurrent 
recorded in both groups after 2 weeks of treat-
ment (GUPI change: control group = 6.75, TW 
see Fig. 5). However, this could also be a result 
of central desensitizing elements of the multi-
modal treatment, such as PFM release exercises 
or mindfulness relaxation.
groups during the initial 6- week treatment pe-
riod, and declined in intensity over time. It may 
the initial rehabilitation process, which would be 
an important clinical observation of the present 
-
ment commenced, which was not expected, and 
up intensity over time. This is in keeping with 
the reported patient experience that physiother-
(Sutcliffe et al. 2015b), and further investigation 
is required to observe the natural progression 
treatment.
After 6 weeks of physiotherapy treatment, the 
TW group demonstrated a greater reduction in 
all symptom and bother scores than the control 
group, and the difference between groups was at 
least a further half of the MCID score (Tables 4 
& 5). The change in the control group was 
comparable to those of FitzGerald et al. (2012) 
(score change: ICSI = 3.2 ± 3.7, ICPI = 3.6 ± 3.6, 
P = 0.0012 for both), as would be expected of a 
similar intervention. However, the difference in 
ICSI score achieved by the TW group at 6 weeks 
was double that of the physiotherapist- applied 
MFR in the FitzGerald et al. (2012) study after 
-
tial for TW use to enhance treatment response by 
increasing the frequency of MFR treatment.
-
ous studies, which found that an individualized 
approach to MFR treatment involving vaginal 
access to the PFMs with contract–relax stretch-
all P et al. 
et al. 2009, 2012). Because 
this technique was used for both the manual, 
physiotherapist- applied and TW MFR, TW use 
may have increased the frequency of treatment. 
It has been suggested that gentle contract–relax 
stretching creates presynaptic ischaemic muscle 
inhibition, and produces immediate passive mus-
cle lengthening (Beltrão et al. 2014). This may 
increase the functional movement of the PFMs 
(Khorasani et al. 2012), allowing for neurogenic 
this would produce a concurrent improvement in 
urinary urgency and frequency, as was observed 
in the present study, and therefore, this warrants 
replication in a larger trial to further assess this 
possibility. Thus, an improvement in PFM rest-
ing tension and pain could be said to bring about 
functional improvements in participants’ bladder 
Figure 5. Line graph showing the participant mean visual analogue scale (VAS) score for overall pain over the 
duration of the study in the control (––) and therapeutic wand (- - - - ) groups.
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symptoms (ICSI change: control group = 4.25, 
Urgency Frequency Patient Symptom Scale 
change: control group = 3.75, TW group = 6.8), 
symptoms observed by increasing the frequency 
of PFM treatment.
A trend for continuing improvement in the TW 
group and a plateau in the control group during 
the follow- up period was observed across all the 
outcome measures (see Tables 4 & 5), and this 
et al. 
(2011a) only recorded monthly measures during 
a more- intense intervention that varied too much 
from the current protocol for a comparison to 
be made. The repeated measures recorded in the 
present study hint at the potential for clinically 
useful information to be gleaned from more- 
frequent assessment during the study period, and 
a longer follow- up duration would also allow for 
further extrapolation of any difference between 
their self- management.
Kaptchuck et al. (2000) discussed the poten-
tial of a heightened placebo response to medi-
cal devices, as observed with sham acupuncture 
and transcutaneous electrical nerve stimulation 
machine use, where a baseline placebo response 
to a device may impact the observed results and 
lead to misinterpretation. In the present study, 
participants may have had a placebo- driven re-
sponse to TW use. A further investigation could 
consider a third TW control group to assess 
for this effect: participants could be provid-
ed with a TW and taught only external pelvic 
massage.
The continued improvement observed in the 
TW group after the physiotherapist- applied MFR 
-
ing of the present research. While a larger- scale 
sound theoretical basis for the mechanism by 
which the TW may improve outcomes exists. 
Providing participants with the ability and knowl-
edge to change their symptoms may, in itself, 
have improved their reported pain and disability, 
and may account for the continued score chang-
known to be enhanced by improving patients’ 
perceptions of their control of their health status 
(Dufour et al. 2015): it provides an internal moti-
vation to self- manage symptoms (Anderson et al. 
2002), and in turn, this is known to improve 
outcomes (Bodenheimer et al. 2002). In patients 
most important element of how they determine 
their disability (Denison et al.2004), and Blyth 
et al. (2004) found that active self- management 
reduces the likelihood of pain- related disability 
(adjusted odds ratio = 0.2).
The TW also represents a potential BPS self- 
management strategy, giving sufferers the op-
portunity for timely treatment of their symptom 
appointment. The prevalence of sexual abuse is 
known to be slightly higher in those with BPS 
than in the general population (Warren et al. 
2011), and undergoing regular intravaginal treat-
ment has the potential to unlock experiences 
or to create distress (Peters 2010). Therefore, 
patients who are averse to hospital- based intra-
vaginal treatment or unable to attend it would 
be able to access treatment independently in 
their own home by using a TW, reducing the 
need for potentially embarrassing or distressing 
internal treatment at the physiotherapy clinic. 
Promoting the concurrent use of a TW may also 
reduce the burden on stretched physiotherapy 
services, which previously had to provide the 
required labour- intensive treatment by reducing 
the necessary treatment duration. There is also 
the potential for physiotherapist contact to reduce 
management with TW use, changing the thera-
pist’s role to that of a guide to self- management, 
providing manual therapy only to those who are 
struggling with self- management. Therefore, the 
potential for patients to have access to enhanced 
physiotherapy intervention and effective self- 
treatment, and the possibility of a reduction in 
the demand on physiotherapy services warrants 
further investigation.
the present study are unclear because the small 
sample allowed only limited data analysis. 
Volunteer sampling may have skewed the re-
sults towards those willing to self- treat with a 
TW, as shown by the high compliance with TW 
use. Therefore, the acceptability of independ-
ent intravaginal treatment requires further in-
vestigation. Exclusion of non- bladder conditions 
known to be risk factors for BPS development 
may have overtly limited the sample, and there-
wider population with BPS. The lack of assessor 
blinding was a pragmatic step to ensure partici-
pant safety in a small pilot, and this may have 
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The methods trialled proved to be feasible and 
an RCT. Collaboration over multiple sites should 
which was prolonged in the present single- site 
pilot. Prospective convenience sampling from 
clinics would improve the rate of recruitment, 
and also reduce the bias of a motivated vol-
unteer sample. Assessing vaginal resting tone 
and PFM movement would improve the under-
standing of underlying treatment mechanisms. 
Assessor blinding should be used to improve 
study validity.
The present pilot study has demonstrated that 
the RCT method is feasible.
Using a TW twice weekly appears to be a use-
ful clinical adjunct to physiotherapy treatment. 
Both groups achieved a clinically meaningful 
change in symptom score during the initial treat-
ment period that was maintained at follow- up. 
However, the use of a TW appears to have en-
hanced the physiotherapy treatment received, and 
improved the maintenance of therapy gains dur-
ing the follow- up period. It is unknown whether 
this was because of the increased frequency of 
MFR treatment received by those using a TW, or 
improvement in physiotherapy treatment carry- 
over or the effect of improving participants’ lo-
cus of control for their health status.
the TW may provide a suitable and safe self- 
management tool for patients suffering from 
BPS. This would potentially give sufferers the 
opportunity for timely treatment of symptom 
-
therapy appointment. Patients who are averse to 
hospital- based intravaginal treatment or unable to 
attend it would have the option of accessing the 
their own home, and the pressure on stretched 
physiotherapy departments to provide labour- 
intensive treatment might be reduced.
The feasibility of conducting an RCT investi-
gating the use of a TW in women with BPS has 
been demonstrated, and some areas where the 
method could be adapted have been highlighted. 
Caution must be applied so as not to infer signif-
study. However, the clinically meaningful chang-
es observed warrant further examination with an 
appropriately powered RCT given the potential 
those living with BPS. Further qualitative inves-
tigations of the lived experience of women self- 
managing the symptoms of BPS using a TW are 
also required to ascertain the acceptability, and 
TW.
TheraWand® provided the TWs used in this re-
search free of charge. No other sources of fund-
ing were used.
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The information sheet that the TW group was provided with is shown in Fig. 6.
Figure 6. Information sheet given to the therapeutic wand group.
